Cutaneous Myiasis in Rural Haiti.

Background: Myiasis is a disease caused by the infestation of human tissue by the larval stage of various flies. It has been identified in sub-Saharan Africa and in tropical parts of the Americas. Cases have also been identified among travelers returning to the United States. Infestations may involve any part of the body, including the scalp, and open wounds may become infected with these larvae. The primary cause of wound myiasis in the western hemisphere is Cochliomyia hominivorax. Case Report: We present a case of wound myiasis in an adult Haitian male with a persistent wound for 2 years. To our knowledge, only 1 other report of wound myiasis in Haiti caused by C hominivorax has been published. Conclusion: Wound myiasis can occur in many tropical regions of the world, including Haiti. Because of the prevalence of global travel, clinicians should be familiar with the condition's diagnosis and management.

Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia.

BACKGROUND: This is a Phase I trial demonstrating safety and tolerability of intravaginal curcumin for future use in women with cervical neoplasia. OBJECTIVE: The objective of this study was to assess the safety, tolerability, and pharmacokinetics of intravaginal curcumin in healthy women. STUDY DESIGN: We conducted a 3+3 dose-escalation Phase I trial in a group of women aged 18-45 years. Thirteen subjects were given one of four doses of curcumin powder (500 mg, 1,000 mg, 1,500 mg, and 2,000 mg) packed in gelatin capsules, which was administered intravaginally daily for 14 days. The primary end point for this study was safety based on severe adverse events regarding laboratory toxicity, clinical findings, and colposcopic abnormalities. We administered an acceptability questionnaire to assess product experience and attributes. RESULTS: No dose-limiting toxicities (0/13) were experienced (95% confidence interval: 0.0%-22.8%) in this study. The pharmacokinetics data demonstrated that curcumin and curcumin conjugates were not measurable in the serum and negligible in the urine of the study participants. Although 23 adverse events occurred during the course of the trial, all events were grade I based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and were resolved by the end of the study in an average of 9 days. Fifty-six percent of the adverse events were related to the study drug, which included genital pruritus (23% of subjects), vaginal discharge (100%), vaginal dryness (15%), abnormal prothrombin (23%), and hypokalemia (8%). CONCLUSION: Intravaginal curcumin was well tolerated by all subjects and safe. In this Phase I trial, there were no severe adverse events observed at any of the administered dose levels. All adverse events were grade I and did not result in early termination of the study. There was no evidence of systemic absorption or significant local absorption of intravaginally administered curcumin.